Severe influenza can lead to significant morbidity and mortality, prompting the exploration of adjunctive therapies such as inhaled nitric oxide (iNO). Nitric oxide has known vasodilatory and anti-inflammatory effects, which theoretically could benefit patients with severe influenza. This study aimed to evaluate the efficacy of iNO therapy in improving outcomes in an experimental model of severe influenza. We conducted a controlled experimental study using [specific animal model or cell line] to simulate severe influenza. Subjects were randomly assigned to receive either inhaled nitric oxide or a placebo. Outcomes measured included survival rates, viral load, lung inflammation, and overall clinical scoring based on disease severity. The administration of inhaled nitric oxide did not lead to a statistically significant improvement in survival rates, reduction in viral load, or amelioration of lung inflammation compared to the placebo group. Clinical scoring of disease severity showed no notable differences between the iNO and control groups. Our findings suggest that inhaled nitric oxide therapy does not confer a beneficial effect on outcomes in experimental severe influenza. Further research may be needed to explore alternative therapeutic approaches or to identify specific patient populations that could potentially benefit from iNO therapy.

Inhaled nitric oxide, severe influenza, experimental model

[Internet] WHO: Geneva, Switzerland. Fact sheet 211, Influenza http://www.who.int/mediacentre/factsheets/fs211/en/

Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008; 52: 3284–92.

[Internet] CDC. 2008–2009 Influenza season week 39 ending October 3, 2009. http://www.cdc.gov/flu/weekly/ weeklyarchives2008-2009/weekly39.htm

[Internet] WHO: Geneva, Switzerland. Influenza A (H1N1) virus resistance to oseltamivir. http://www.who.int /influenza/resources/documents/H1N1webupdate20090318_ ed_ns.pdf

[Internet] WHO: Geneva, Switzerland. Weekly update on oseltamivir resistance to influenza H1N1 (2009) viruses. http://www.who.int/influenza/2011_02_11_weekly_web_up date_oseltamivir_resistance.pdf

[Internet] WHO: Geneva, Switzerland. Weekly epidemiological record. 2011; 86: 81–92. http://www.who.int/wer/2011/ wer8610.pdf

Le QM, Kiso M, Someya K, et al. Avian flu: Isolation of drug-resistant H5N1 virus. Nature 2005; 437: 1108.

De Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005; 353: 2667–72.

Sheu TG, Fry AM, Garten RJ, et al. Dual resistance to adamantanes and oseltamivir among seasonal influenza A (H1N1) viruses: 2008–2010. J Infect Dis. 2011; 203: 13–17.

Murphy BR, Baron S, Chalhub EG, Uhlendorf CP, Chanock RM. Temperature-sensitive mutants of influenza virus. IV. Induction of interferon in the nasopharynx by wild-type and a temperature- sensitive recombinant virus. J Infect Dis. 1973; 128: 488–93.

Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003; 51: 123–29.

Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: A case series. Lancet 2008; 372: 744–49.

Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med. 2009; 361: 1935–44.

To K , Hung I , Li I, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010; 50: 850–59.

Kumar A. Early versus late oseltamivir treatment in severly ill patients with 2009 pandemic influenza A (H1N1): speed is life. J Antimicrob Chemother. 2011; 66: 959–63